nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.02.2016 | Neuro-oncology (L A Abrey, Section Editor)

Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma

verfasst von: Peter M. Clark, Wilson X. Mai, Timothy F. Cloughesy, David A. Nathanson

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Malignant gliomas are intractable and among the most lethal human malignancies. Like other cancers, metabolic reprogramming is a key feature of glioma and is thought to accommodate the heightened nutrient requirements for tumor cell proliferation, growth, and survival. This metabolic rewiring, driven by oncogenic signaling and molded by the unique environment of the brain, may impose vulnerabilities that could be exploited therapeutically for increased tumor control. In this review, we discuss the prominent metabolic features of malignant glioma, the key pathways regulating glioma metabolism, and the potential therapeutic opportunities for targeting metabolic processes.

Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra0708126.CrossRefPubMed

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. doi:10.1056/NEJMoa043330.CrossRefPubMed

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8. doi:10.1038/nature07385.

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77. doi:10.1016/j.cell.2013.09.034.PubMedCentralCrossRefPubMed

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-oncology. 2015;17(8):1051–63. doi:10.1093/neuonc/nov031.CrossRefPubMed

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012;2(5):458–71. doi:10.1158/2159-8290.CD-11-0284.PubMedCentralCrossRefPubMed

Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, et al. De-repression of PDGFRbeta transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013;3(5):534–47. doi:10.1158/2159-8290.CD-12-0502.PubMedCentralCrossRefPubMed

Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343(6166):72–6. doi:10.1126/science.1241328.PubMedCentralCrossRefPubMed

Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. J Exp Med. 2012;209(2):211–5. doi:10.1084/jem.20120162.PubMedCentralCrossRefPubMed

10.

Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427–33. doi:10.1016/j.tibs.2010.05.003.PubMedCentralCrossRefPubMed

11.

Jelluma N, Yang X, Stokoe D, Evan GI, Dansen TB, Haas-Kogan DA. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res MCR. 2006;4(5):319–30. doi:10.1158/1541-7786.MCR-05-0061.CrossRefPubMed

12.

Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, et al. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol. 2012;8:589. doi:10.1038/msb.2012.20.PubMedCentralCrossRefPubMed

13.

Kennedy CR, Tilkens SB, Guan H, Garner JA, Or PM, Chan AM. Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions. Cancer Lett. 2013;336(2):299–306. doi:10.1016/j.canlet.2013.03.020.CrossRefPubMed

14.

Fack F, Espedal H, Keunen O, Golebiewska A, Obad N, Harter PN, et al. Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol. 2015;129(1):115–31. doi:10.1007/s00401-014-1352-5.PubMedCentralCrossRefPubMed

15.

Oudard S, Arvelo F, Miccoli L, Apiou F, Dutrillaux AM, Poisson M, et al. High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer. 1996;74(6):839–45.PubMedCentralCrossRefPubMed

16.

Chinnaiyan P, Kensicki E, Bloom G, Prabhu A, Sarcar B, Kahali S, et al. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res. 2012;72(22):5878–88. doi:10.1158/0008-5472.CAN-12-1572-T.PubMedCentralCrossRefPubMed

17.

Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci. 2013;16(10):1373–82. doi:10.1038/nn.3510.PubMedCentralCrossRefPubMed

18.

Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell. 2007;18(4):1437–46. doi:10.1091/mbc.E06-07-0593.PubMedCentralCrossRefPubMed

19.

Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988–1004. doi:10.1038/nrd1902.CrossRefPubMed

20.

Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001;15(11):1406–18. doi:10.1101/gad.889901.PubMedCentralCrossRefPubMed

21.

Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011;208(2):313–26. doi:10.1084/jem.20101470.PubMedCentralCrossRefPubMed

22.

Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem. 1997;272(28):17269–75.CrossRefPubMed

23.

Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014;4(4):423–33. doi:10.1158/2159-8290.CD-13-0440.PubMedCentralCrossRefPubMed

24.

Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501. doi:10.1038/nrc839.CrossRefPubMed

25.

Carriere A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, et al. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol. 2008;18(17):1269–77. doi:10.1016/j.cub.2008.07.078.CrossRefPubMed

26.

Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177–85. doi:10.1016/j.cmet.2006.02.002.CrossRefPubMed

27.•

Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013;18(5):726–39. doi:10.1016/j.cmet.2013.09.013. The authors show that mTORC2, a central signaling node downstream of RTK-PI3K signaling, can regulate GBM glycolytic flux further demonstrating a critical link between aberrant signal transduction and tumor metabolism.CrossRefPubMed

28.

Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro-Oncology. 2010;12(11):1102–12. doi:10.1093/neuonc/noq080.PubMedCentralCrossRefPubMed

29.

Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230–3. URL: http://www.nature.com/nature/journal/v452/n7184/suppinfo/nature06734_S1.html.

30.

Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008;452(7184):181–6. URL: http://www.nature.com/nature/journal/v452/n7184/suppinfo/nature06667_S1.html.

31.

Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009;2(97):ra73. doi:10.1126/scisignal.2000431.PubMedCentralCrossRefPubMed

32.

Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA. 2012;109(18):6904–9. doi:10.1073/pnas.1204176109.PubMedCentralCrossRefPubMed

33.

Lunt SY, Muralidhar V, Hosios AM, Israelsen WJ, Gui DY, Newhouse L, et al. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol Cell. 2015;57(1):95–107. doi:10.1016/j.molcel.2014.10.027.PubMedCentralCrossRefPubMed

34.

Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science. 2011;334(6060):1278–83. doi:10.1126/science.1211485.PubMedCentralCrossRefPubMed

35.

Kung C, Hixon J, Choe S, Marks K, Gross S, Murphy E, et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem Biol. 2012;19(9):1187–98. doi:10.1016/j.chembiol.2012.07.021.PubMedCentralCrossRefPubMed

36.

Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206(Pt 12):2049–57.CrossRefPubMed

37.

Tsao TS, Burcelin R, Charron MJ. Regulation of hexokinase II gene expression by glucose flux in skeletal muscle. J Biol Chem. 1996;271(25):14959–63.CrossRefPubMed

38.••

Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24(2):213–28. doi:10.1016/j.ccr.2013.06.014. Using global hexokinase 2 knockout mice, this paper demonstrated that elimination of hexokinase 2 has profound therapeutic effects on tumor metabolism and growth, without apparent adverse effects on mouse physiology.PubMedCentralCrossRefPubMed

39.

Xu Y, Liu X-H, Saunders M, Pearce S, Foulks JM, Parnell KM, et al. Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2). Bioorg Med Chem Lett. 2014;24(2):515–9. doi:10.1016/j.bmcl.2013.12.028.CrossRefPubMed

40.

Parnell KM, Foulks JM, Nix RN, Clifford A, Bullough J, Luo B, et al. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol Cancer Ther. 2013;12(8):1453–60. doi:10.1158/1535-7163.MCT-13-0026.CrossRefPubMed

41.

Guo C, Linton A, Jalaie M, Kephart S, Ornelas M, Pairish M, et al. Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators. Bioorg Med Chem Lett. 2013;23(11):3358–63. doi:10.1016/j.bmcl.2013.03.090.CrossRefPubMed

42.

Boxer MB, Jiang J-K, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, et al. Evaluation of substituted N, N′-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J Med Chem. 2010;53(3):1048–55. doi:10.1021/jm901577g.PubMedCentralCrossRefPubMed

43.

Walsh MJ, Brimacombe KR, Veith H, Bougie JM, Daniel T, Leister W, et al. 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett. 2011;21(21):6322–7. doi:10.1016/j.bmcl.2011.08.114.PubMedCentralCrossRefPubMed

44.

J-k J, Boxer MB, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, et al. Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett. 2010;20(11):3387–93. doi:10.1016/j.bmcl.2010.04.015.CrossRef

45.

Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8(10):839–47. doi:10.1038/nchembio.1060.PubMedCentralCrossRefPubMed

46.

Bluemlein K, Grüning N-M, Feichtinger RG, Lehrach H, Kofler B, Ralser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. 2011

47.

Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009;27(7):1082–6. doi:10.1200/jco.2008.19.1098.PubMedCentralCrossRefPubMed

48.

Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neuro-Oncol. 2014;117(1):125–31. doi:10.1007/s11060-014-1362-0.CrossRef

49.

Rieger J, Bahr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44(6):1843–52. doi:10.3892/ijo.2014.2382.PubMedCentralPubMed

50.

Stafford P, Abdelwahab MG, do Kim Y, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond). 2010;7:74. doi:10.1186/1743-7075-7-74.CrossRef

51.

Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One. 2012;7(5), e36197. doi:10.1371/journal.pone.0036197.PubMedCentralCrossRefPubMed

52.

Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011;11:315. doi:10.1186/1471-2407-11-315.PubMedCentralCrossRefPubMed

53.

Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012;15(6):827–37. doi:10.1016/j.cmet.2012.05.001.PubMedCentralCrossRefPubMed

54.

Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Matés JM, et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci. 2011;108(21):8674–9. doi:10.1073/pnas.1016627108.PubMedCentralCrossRefPubMed

55.

Maher EA, Marin-Valencia I, Bachoo RM, Mashimo T, Raisanen J, Hatanpaa KJ, et al. Metabolism of [U-13 C]glucose in human brain tumors in vivo. NMR Biomed. 2012;25(11):1234–44. doi:10.1002/nbm.2794.PubMedCentralCrossRefPubMed

56.

Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 2013;36(10):587–97. doi:10.1016/j.tins.2013.07.001.PubMedCentralCrossRefPubMed

57.••

Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159(7):1603–14. doi:10.1016/j.cell.2014.11.025. Using 13C-NMR analysis of patient-derived mouse orthotopic brain tumor, this elegant study demonstrates for the first time that GBM consume and oxidize acetate as an energetic substrate. This paper also shows, in their models, that GBM tumors do not oxidize consumed glutamine.PubMedCentralCrossRefPubMed

58.

Janiszewska M, Suva ML, Riggi N, Houtkooper RH, Auwerx J, Clement-Schatlo V, et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012;26(17):1926–44. doi:10.1101/gad.188292.112.PubMedCentralCrossRefPubMed

59.

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12. doi:10.1126/science.1164382.PubMedCentralCrossRefPubMed

60.

Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PloS One. 2011;6(5), e19868. doi:10.1371/journal.pone.0019868.PubMedCentralCrossRefPubMed

61.

Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010;465(7300):966. doi:10.1038/nature09132.PubMedCentralCrossRefPubMed

62.

Birner P, Pusch S, Christov C, Mihaylova S, Toumangelova-Uzeir K, Natchev S, et al. Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. Cancer. 2014;120(16):2440–7. doi:10.1002/cncr.28732.CrossRefPubMed

63.•

Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, et al. 2-Hydroxyglutarate inhibits ATP synthase and mTOR signaling. Cell Metab. 2015;22(3):508–15. doi:10.1016/j.cmet.2015.06.009. This work demonstrated that the oncometabolite, 2-HG, can inhibit ATP synthase and mTOR in glioma cells.CrossRefPubMed

64.

Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, et al. Lactate dehydrogenase a silencing in IDH mutant gliomas. Neuro-oncology. 2014;16(5):686–95. doi:10.1093/neuonc/not243.PubMedCentralCrossRefPubMed

65.

Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, et al. IDH1 mutation induces reprogramming of pyruvate metabolism. Cancer Res. 2015;75(15):2999–3009. doi:10.1158/0008-5472.CAN-15-0840.CrossRefPubMed

66.

Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, et al. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35(6):5911–20. doi:10.1007/s13277-014-1784-5.CrossRef

67.

Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30. doi:10.1016/j.ccr.2010.12.014.PubMedCentralCrossRefPubMed

68.

Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324(5924):261–5. doi:10.1126/science.1170944.PubMedCentralCrossRefPubMed

69.

Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012;483(7390):484–8. doi:10.1038/nature10898.PubMedCentralCrossRefPubMed

70.

Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2(31):31ra4. doi:10.1126/scitranslmed.3000677.CrossRef

71.

Garon E, Christofk H, Hosmer W, Britten C, Bahng A, Crabtree M, et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2014;140(3):443–52. doi:10.1007/s00432-014-1583-9.PubMedCentralCrossRefPubMed

72.

Davis M, Pragani R, Popovici-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: a potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.

73.

Zheng B, Yao Y, Liu Z, Deng L, Anglin JL, Jiang H, et al. Crystallographic investigation and selective inhibition of mutant isocitrate dehydrogenase. ACS Med Chem Lett. 2013;4(6):542–6. doi:10.1021/ml400036z.PubMedCentralCrossRefPubMed

74.••

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626–30. doi:10.1126/science.1236062. Genomic studies of GBM suggest that mutant IDH1 may drive GBM growth and survival. This paper identifies a selective inhibitor of mutant IDH1 which blocks the growth of IDH1-mutant, but importantly not IDH1-wild-type, tumors.PubMedCentralCrossRefPubMed

75.

Deng G, Shen J, Yin M, McManus J, Mathieu M, Gee P, et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J Biol Chem. 2015;290(2):762–74. doi:10.1074/jbc.M114.608497.PubMedCentralCrossRefPubMed

76.

Wu F, Jiang H, Zheng B, Kogiso M, Yao Y, Zhou C, et al. Inhibition of cancer-associated mutant isocitrate dehydrogenases by 2-thiohydantoin compounds. J Med Chem. 2015;58(17):6899–908. doi:10.1021/acs.jmedchem.5b00684.CrossRefPubMed

77.

Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap J, et al. Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198. Cancer Res. 2015. doi:10.1158/0008-5472.CAN-14-3603.PubMed.PubMed

78.

Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A. 2009;106(31):12932–7. doi:10.1073/pnas.0906606106.PubMedCentralCrossRefPubMed

79.

Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal. 2009;2(101):ra82. doi:10.1126/scisignal.2000446.PubMedCentralCrossRefPubMed

80.

Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, et al. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res. 2013;73(9):2850–62. doi:10.1158/0008-5472.CAN-13-0382-T.PubMedCentralCrossRefPubMed

81.

Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S America. 2000;97(16):9226–33.CrossRef

82.

Spence AM, Muzi M, Mankoff DA, O’Sullivan SF, Link JM, Lewellen TK, et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med. 2004;45(10):1653–9.PubMed

83.

Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. 18F-FDOPA kinetics in brain tumors. J Nucl Med Off Publ Soc Nucl Med. 2007;48(10):1651–61. doi:10.2967/jnumed.106.039321.

84.

Grassi I, Nanni C, Allegri V, Morigi JJ, Montini GC, Castellucci P, et al. The clinical use of PET with (11)C-acetate. Am J Nucl Med Mol Imaging. 2012;2(1):33–47.PubMedCentralPubMed

85.

Lieberman BP, Ploessl K, Wang L, Qu W, Zha Z, Wise DR, et al. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med Off Publ Soc Nucl Med. 2011;52(12):1947–55. doi:10.2967/jnumed.111.093815.

86.

Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, et al. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Transl Med. 2015;7(274):274ra17. doi:10.1126/scitranslmed.aaa1009.CrossRef

87.

Horska A, Barker PB. Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin N Am. 2010;20(3):293–310. doi:10.1016/j.nic.2010.04.003.PubMedCentralCrossRefPubMed

88.

Kwock L, Smith JK, Castillo M, Ewend MG, Collichio F, Morris DE, et al. Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncol. 2006;7(10):859–68. doi:10.1016/S1470-2045(06)70905-6.CrossRefPubMed

89.

Kalinina J, Carroll A, Wang L, Yu Q, Mancheno DE, Wu S, et al. Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. J Mol Med (Berl). 2012;90(10):1161–71. doi:10.1007/s00109-012-0888-x.CrossRef

90.

Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624–9. doi:10.1038/nm.2682.PubMedCentralCrossRefPubMed

91.

Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4(116):116ra4. doi:10.1126/scitranslmed.3002693.PubMedCentralCrossRefPubMed

92.

Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neuro-Oncol. 2012;107(1):197–205. doi:10.1007/s11060-011-0737-8.CrossRef

93.

Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 2012;4(116ra5):116. doi:10.1126/scitranslmed.3002796.

94.

Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell. 2013;23(3):302–15. doi:10.1016/j.ccr.2013.02.003.PubMedCentralCrossRefPubMed

Titel: Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma
verfasst von: Peter M. Clark
Wilson X. Mai
Timothy F. Cloughesy
David A. Nathanson
Publikationsdatum: 01.02.2016
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 2/2016
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-015-0613-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Developments in Varicella Zoster Virus Vasculopathy

Neurocutaneous Disorders for the Practicing Neurologist: a Focused Review

Optic Perineuritis

Neurogenesis in the Hippocampus of Patients with Temporal Lobe Epilepsy

Current Management of Adult Diffuse Infiltrative Low Grade Gliomas